VANCOUVER, British Columbia, April 2, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) today announced that data from the Phase 1b trial of QLT091001 in subjects with Retinitis Pigmentosa (RP) due to RPE65 and LRAT mutations will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida.
